Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force on the management of acute coronary syndromes of the european society of cardiology

European Heart Journal

Volumn 23, Issue 23, 2002, Pages 1809-1840

  Bertrand, Michel E ^a   Simoons, Maarten L ^a   Fox, Keith A A ^a   Wallentin, Lars C ^a   Hamm, Christian W ^a   McFadden, Eugene ^a   De Feyter, Pim J ^a   Specchia, Giuseppe ^a   Ruzyllo, Witold ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute coronary syndromes; Coronary bypass surgery; Non Q wave myocardial infarction; Percutaneous transluminal coronary angioplasty; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DILTIAZEM; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HIRUDIN; IMINE; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; NADROPARIN; NICORANDIL; NIFEDIPINE; NITRATE; POTASSIUM CHANNEL STIMULATING AGENT; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; VERAPAMIL;

ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; DEATH; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG TOLERANCE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LONG TERM CARE; NEUTROPENIA; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS; VASOCONSTRICTION;

ACUTE DISEASE; BIOLOGICAL MARKERS; CORONARY ARTERY BYPASS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; SYNDROME;

EID: 0036892858     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3385     Document Type: Article

References (218)

1. Davies MJ, Richardson PJ, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-81.
2. Davies M. Acute coronary thrombosis: The role of plaque disruption and its initiation and prevention. Eur Heart J 1995; 16 (Suppl L): 3-7.
3. Davies M. The composition of coronary artery plaque. N Engl J Med 1997; 336: 1312-13.
4. Task force on the management of acute myocardial infarction of the European Society of Cardiology. Acute myocardial infarction: Prehospital and in-hospital management. Eur Heart J (in Press).
5. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.
6. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.
7. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000; 102: 1193-209.
8. Hall R. Guidelines on the management of unstable angina. Heart 2001; 85: 132.
9. Verstraete M, Prentice CR, Samama M, Verhaeghe R. A European view on the North American fifth consensus on antithrombotic therapy. Chest 2000; 117: 1755-70.
10. Schwartz PJ, Breithardt G, Howard AJ, Julian DG, Rehnqvist Ahlberg N. Task Force Report: The legal implications of medical guidelines. A Task Force of the European Society of Cardiology. Eur Heart J 1999; 20: 1152-7.
11. Battler A. European Heart Survey of Acute Coronary syndromes. Eur Heart J 2002; 23: 1190-201
12. Fox K, Goodman S, Klein W, Brieger D, Steg P, Dabbous O, Avezum A. Managements of acute coronary syndromes. Variations in practice and outcome: Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89.
13. GRACE I. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001; 141: 190-9.
14. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: Findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359: 373-7.
15. Fuster VBL, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50, 310-18.
16. Fuster V. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994; 90: 2126-46.
17. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
18. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.
19. Burke APFA, Tang AL. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-82.
20. Davies MJ. Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-20.
21. Farb ABA, Tang AL. Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354-63.
22. Arbustini EDBB, Morbini P, Burke AP, Bocciarelli M, Specchia G, Virmani. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 1999; 82: 269-72.
23. Libby P. Molecular basis of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
24. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-8.
25. Kaartinen M, van der Wal A, van der Loos C. Mast cell infiltration in acute coronary syndromes: Implications for plaque rupture. J Am Coll Cardiol 1998; 32: 606-12.
26. Arbustini E, De Servi S, Bramucci E et al. Comparison of coronary lesions obtained by directional coronary atherectomy in unstable angina, stable angina, and restenosis after either atherectomy or angioplasty. Am J Cardiol 1995; 75: 675-82.
27. Arbustini E, Morbini P, De Servi S et al. Histopathologic features in atherectomy samples obtained from patient with unstable angina, stable angina and restenosis. Directional Atherectomy Lombardi Group. G Ital Cardiol 1996; 26: 623-33.
28. Toschi VGR, Lettino M., Fallon JT. Tissue factor predicts the thrombogenicity of human atherosclerotic components. Circulation 1997; 95: 594-9.
29. Willerson JTGP, Eidt J, Campbell WB, Buja M. Specific platelet mediators and unstable coronary artery lesions: Experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205.
30. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989; 63: 114E-120E.
31. Falk E, Fuster V. Angina pectoris and disease progression. Circulation 1995; 92: 2033-5.
32. Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
33. van Domburg RT, van Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: Good long-term outcome after a complicated early course. J Am Coll Cardiol 1998; 31: 1534-9.
34. Lee TH, Cook EF, Weisberg M, Sargent RK, Wilson C, Goldman L. Acute chest pain in the emergency room. Identification and examination of low-risk patients. Arch Intern Med 1985; 145: 65-9.
35. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain. Ann Emerg Med 1998; 31: 3-11.
36. Fisch C. The Clinical ECG; Sensitivity and Specificity. Elsevier, 1997.
37. Savonitto S, Ardissino D, Granger CB et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281: 707-13.
38. Rouan GW, Lee TH, Cook EF, Brand DA, Weisberg MC, Goldman L. Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study). Am J Cardiol 1989; 64: 1087-92.
39. McCarthy BD, Wong JB, Selker HP. Detecting acute cardiac ischemia in the emergency department: A review of the literature. J Gen Intern Med 1990; 5: 365-73.
40. Pozen MW, D'Agostino RB, Selker HP, Sytkowski PA, Hood WB Jr. A predictive instrument to improve coronarycare-unit admission practices in acute ischemic heart disease. A prospective multicenter clinical trial. N Engl J Med 1984; 310: 1273-8.
41. Davies E, Gawad Y, Takahashi M et al. Analytical performance and clinical utility of a sensitive immunoassay for determination of human cardiac troponin I. Clin Biochem 1997; 30: 479-90.
42. Katus HA, Looser S, Hallermayer K et al. Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chem 1992; 38: 386-93.
43. Jaffe AS, Ravkilde J, Roberts R et al. It's time for a change to a troponin standard. Circulation 2000; 102: 1216-20.
44. Giannitsis E, Muller-Bardorff M, Kurowski V et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000; 102: 211-17.
45. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997; 96: 2953-8.
46. Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997; 30: 1354-9.
47. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 1997; 95: 163-8.
48. McLaurin MD, Apple FS, Voss EM, Herzog CA, Sharkey SW. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: Evidence of cardiac troponin T expression in skeletal muscle. Clin Chem 1997; 43: 976-82.
49. Frankel WL, Herold DA, Ziegler TW, Fitzgerald RL. Cardiac troponin T is elevated in asymptomatic patients with chronic renal failure. Am J Clin Pathol 1996; 106: 118-23.
50. Labugger R, Organ L, Collier C, Atar D, Van Eyk JE. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000; 102: 1221-6.
51. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.
52. FRISC II investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 708-15.
53. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: A FRISC II substudy. J Am Coll Cardiol 2001; 38: 979-86.
54. Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem 1999; 45: 1104-21.
55. Cohen M, Demers C, Gurfinkel EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.
56. Campbell RWF, Turpie AGG, Maseri A et al. Management strategies for a better outcome in unstable coronary artery disease. Clin Cardiol 1998; 21: 314-22.
57. Braunwald E, Jones RH, Mark DB et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90: 613-22.
58. Theroux P, Fuster V. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction. Circulation 1998; 97: 1195-206.
59. Braunwald E. Unstable angina. A classification. Circulation 1989; 80: 410-14.
60. van Miltenburg-van Zijl AJ, Simoons ML, Veerhoek RJ, Bossuyt PM. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. J Am Coll Cardiol 1995; 25: 1286-92.
61. Nyman I, Areskog M, Areskog NH, Swahn E, Wallentin L. Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group. J Intern Med 1993; 234: 293-301.
62. Diderholm E, Andren B, Frostfeldt G et al. The Fast Revascularization during InStability in Coronary artery d. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease. The FRISC II ECG substudy. Eur Heart J 2002; 23: 41-9.
63. TIMI IIIB investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89: 1545-56.
64. Andersen K, Eriksson P. Ischaemia detected by continuous on-line vectocardiographic monitoring predictes unfavourable outcome in patients admitted with probable unstable coronary artery disease. Coron Artery Dis 1996; 7: 753-60.
65. Gottlieb SO, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med 1986; 314: 1214-19.
66. Langer A, Freeman MR, Armstrong PW. ST segment shift in unstable angina: Pathophysiology and association with coronary anatomy and hospital outcome. J Am Coll Cardiol 1989; 13: 1495-502.
67. Larsson H, Areskog M, Areskog NH et al. The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction. Eur Heart J 1995; 16: 888-93.
68. Wilcox I, Ben Freedman S, Kelly DT, Harris PJ. Clinical significance of silent ischemia in unstable angina pectoris. Am J Cardiol 1990; 65: 1313-16.
69. Patel DJ, Holdright DR, Knight CJ et al. Early continuous ST segment monitoring in unstable angina: Prognostic value additional to the clinical characteristics and the admission electrocardiogram. Heart 1996; 75: 222-8.
70. Akkerhuis KM, Klootwijk PA, Lindeboom W et al. Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events; meta-analysis of three studies involving 995 patients. Eur Heart J 2001; 22: 1997-2006.
71. Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 1998; 81: 1405-10.
72. Ottani F, Galvani M, Nicolini FA et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 140: 917-27.
73. Morrow DA, Cannon CP, Rifai N et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: Results from a randomized trial. JAMA 2001; 286: 2405-12.
74. Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, Goldmann B, Katus HA. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146-50.
75. Pettersson T, Ohlsson O, Tryding N. Increased CKMB (mass concentration) in patients without traditional evidence of acute myocardial infarction. A risk indicator of coronary death. Eur Heart J 1992; 13: 1387-92.
76. Ravkilde J, Hansen AB, Horder M, Jorgensen PJ, Thygesen K. Risk stratification in suspected acute myocardial infarction based on a sensitive immunoassay for serum creatine kinase isoenzyme MB. A 2-5-year follow-up study in 156 consecutive patients. Cardiology 1992; 80: 143-51.
77. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prospective study of the role of cardiac troponin T in patients admitted with unstable angina. BMJ 1996; 313: 262-4.
78. Wu AH, Abbas SA, Green S et al. Prognostic value of cardiac troponin T in unstable angina pectoris. Am J Cardiol 1995; 76: 970-2.
79. Lindahl B. Biochemical markers of myocardial damage for early diagnosis and prognosis in patients with acute coronary syndromes. Minireview based on a doctorial thesis. Ups J Med Sci 1996; 101: 193-232.
80. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 1996; 93: 1651-7.
81. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. J Am Coll Cardiol 1997; 29: 43-8.
82. Antman EM, Tanasijevic MJ, Thompson B et al. Cardiacspecific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-9.
83. Luscher MS, Thygesen K, Ravkilde J, Heickendorff L. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease. TRIM Study Group. Thrombin Inhibition in Myocardial ischemia. Circulation 1997; 96: 2578-85.
84. Galvani M, Ottani F, Ferrini D et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation 1997; 95: 2053-9.
85. Lindahl B, Andren B, Ohlsson J, Venge P, Wallentin L. Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group. Eur Heart J 1997; 18: 762-70.
86. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343: 1139-47.
87. Holmvang LAK, Andersen K, Dellborg M et al. Relative contributions of a single-admission 12-lead electrocardiogram and early 24-hour continuous electrocardiographic monitoring for early risk stratification in patients with unstable coronary artery disease. Am J Cardiol 1999; 83: 667-74.
88. Dellborg M, Andersen K. Key factors in the identification of the high-risk patient with unstable coronary artery disease: Clinical findings, resting 12-lead electrocardiogram, and continuous electrocardiographic monitoring. Am J Cardiol 1997; 80: 35E-39E.
89. Hamm CW, Heeschen C, Goldmann B et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340: 1623-9.
90. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999; 354: 1757-62.
91. Newby LK, Ohman EM, Christenson RH et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: The paragon-B troponin T substudy. Circulation 2001; 103: 2891-6.
92. Morrow DA, Antman EM, Tanasijevic M et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: A TIMI-11B substudy. J Am Coll Cardiol 2000; 36: 1812-17.
93. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96: 4204-10.
94. Becker RCC, Bovill E et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial). Am J Cardiol 1996; 78: 142-7.
95. Pollak H, Fischer M, Fritsch S, Enenkel W. Are admission plasma fibrinogen levels useful in the characterization of risk groups after myocardial infarction treated with fibrinolysis? Thromb Haemost 1991; 66: 406-9.
96. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537-47.
97. de Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
98. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: Effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 2107-13.
99. O'Malley T, Ludlam CA, Riemermsa RA, Fox KA. Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes. Eur Heart J 2001; 22: 1226-34.
100. Ardissino D, Merlini PA, Gamba G et al. Thrombin activity and early outcome in unstable angina pectoris. Circulation 1996; 93: 1634-9.
101. Ernofsson M, Strekerud F, Toss H, Abildgaard U, Wallentin L, Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998; 79: 491-4.
102. Meade TW. Routine measurement of fibrinogen concentration. Clinically feasible. BMJ 1993; 307: 1562.
103. Meade TW, Cooper JA, Chakrabarti R, Miller GJ, Stirling Y, Howarth DJ. Fibrinolytic activity and clotting factors in ischaemic heart disease in women. BMJ 1996; 312: 1581.
104. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J 1995; 16 (Suppl A): 31-4.
105. Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990; 11: 525-8.
106. Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
107. Kruskal JCP, Franks J, Kirsch R. Fibrin and fibrinogenrelated antigens in patients with stable and unstable coronary artery disease. N Eng J Med 1987; 22: 1361-5.
108. Wilcox I, Freedman SB, Allman KC et al. Prognostic significance of a predischarge exercise test in risk stratification after unstable angina pectoris. J Am Coll Cardiol 1991; 18: 677-83.
109. Wilcox I, Ben Freedman SB, Li JN, Harris PJ, Kelly DT. Comparison of exercise stress testing with ambulatory electrocardiographic monitoring in the detection of myocardial ischemia after unstable angina pectoris. Am J Cardiol 1991; 67: 89-91.
110. Launbjerg J, Fruergaard P, Jacobsen HL, Madsen JK. Long-term risk factors from non-invasive evaluation of patients with acute chest pain, but without myocardial infarction. Eur Heart J 1995; 16: 30-7.
111. Nyman I, Wallentin L, Areskog M, Areskog NH, Swahn E. Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group. Int J Cardiol 1993; 39: 131-42.
112. Amanullah AM, Lindvall K, Bevegard S. Exercise echocardiography after stabilization of unstable angina: Correlation with exercise thallium-201 single photon emission computed tomography. Clin Cardiol 1992; 15: 585-9.
113. Amanullah AM, Lindvall K. Predischarge exercise echocardiography in patients with unstable angina who respond to medical treatment. Clin Cardiol 1992; 15: 417-23.
114. Amanullah AM, Lindvall K, Bevegard S. Prognostic significance of exercise thallium-201 myocardial perfusion imaging compared to stress echocardiography and clinical variables in patients with unstable angina who respond to medical treatment. Int J Cardiol 1993; 39: 71-8.
115. Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment [published erratum appears in J Am Coll Cardiol 1991 Sep; 18(3):889]. J Am Coll Cardiol 1991; 17: 1053-7.
116. Luchi RJ, Scott SM, Deupree RH. Comparison of medical and surgical treatment for unstable angina pectoris. Results of a Veterans Administration Cooperative Study. N Engl J Med 1987; 316: 977-84.
117. Telford AMWC. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1: 1225-8.
118. Lubsen JTJ. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: Findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT. Am J Cardiol 1987; 60: 18A-25A.
119. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988; 260: 2259-63.
120. Miami Trial research group. Metoprolol in myocardial infarction. Eur Heart J 1985; 6: 199-226.
121. Kaplan KDR, Parker M, Przybylek J, Teagarden JR, Lesch M. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy. Am J Cardiol 1983; 51: 694-8.
122. DePace N, Herling IM, Kotler MN, Hakki AH, Spielman SR, Segal BL. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action. Arch Intern Med 1982; 142: 1806-9.
123. Roubin GSHP, Eckhardt I et al. Intravenous nitroglycerine in refractory unstable angina pectoris. Aust N Z J Med 1982; 12: 598-602.
124. Curfman G, Heinsimr JA, Lozner EC, Fung HL. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: A prospective randomized trial. Circulation 1983; 67: 276-82.
125. Dellborg M, Gustafsson G, Swedberg K. Buccal versus intravenous nitroglycerin in unstable angina pectoris. Eur J Clin Pharmacol 1991; 41: 5-9.
126. May DCPJ, Podma JJ, Black WH et al. In vivo induction and reversal of nitroglycerin tolerance in human coronary arteries. N Engl J Med 1987; 317: 805-9.
127. Reichek N, Priest C, Zimrin D, Chandler T, Sutton MS. Antianginal effects of nitroglycerin patches. Am J Cardiol 1984; 54: 1-7.
128. Thadani U, Hamilton SF, Olsen E et al. Transdermal nitroglycerin patches in angina pectoris. Dose titration, duration of effect, and rapid tolerance. Ann Intern Med 1986; 105: 485-92.
129. IONA Study Group. Effect of Nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359: 1269-75.
130. Theroux P, Taeymans Y, Morissette D et al. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985; 5: 717-22.
131. Parodi O, Simonetti I, Michelassi C. Comparison of verapamil and propanolol therapy for angina pectoris at rest. A randomized, multiple crossover, controlled trial in the coronary care unit. Am J Cardiol 1986; 57: 899-906.
132. Smith NLRG, Reiberge GE, Psaty BM et al. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina. J Am Coll Cardiol 1998; 32: 1305-11.
133. Gibson RS, Young PM, Boden WE, Schechtman K, Roberts R. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: Results from the Multicenter Diltiazem Reinfarction Study. Am J Cardiol 1987; 60: 203-9.
134. Gibson RS, Hansen JF, Messerli F, Schechtman KB, Boden WE. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: Post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second Danish verapamil infarction trial studies. Am J Cardiol 2000; 86: 275-9.
135. Held PYS, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview. Br Med J 1989; 299: 1187-92.
136. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5.
137. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295-7.
138. Boden WE, van Gilst WH, Scheldewaert RG et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: A randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet 2000; 355: 1751-6.
139. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811-15.
140. Theroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
141. FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996; 347: 561-8.
142. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet 2000; 355: 1936-42.
143. Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.
144. Antman EM, Cohen M, Radley D et al. Assessment of the treatment effect of enoxaparin for unstable Angina/Non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-8.
145. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002; 23: 308-14.
146. Ferguson JJ. Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: The NICE 3 story. National Investigators Collaborating on Enoxaparin. J Invas Cardiol 2000; 12 (Suppl E): E10-3; discussion E25-8.
147. Gusto IIB investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996; 335: 775-82.
148. Fox KA. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials. Am J Cardiol 1999; 84: 26M-31M.
149. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045-8.
150. Cairns JA, Singer J, Gent M et al. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people. Can J Cardiol 1989; 5: 239-46.
151. Antithrombotic, Trialist, Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
152. Balsano F, Rizzon P, Violi F et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990; 82: 17-26.
153. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
154. CAPRIE. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.
155. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-9.
156. Leebeek FWG, Boersma E, Cannon CP, Werf FJJ van de, Simoons ML. Oral glycoprotein IIb/IIIareceptor inhibitors in patients with cardiovascular disease: Why were the results so unfavourable. Eur Heart J 2002; 23: 444-57.
157. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk angioplasty. N Engl J Med 1994; 330: 956-61.
158. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689-96.
159. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
160. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96: 1445-53.
161. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-8.
162. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000; 356: 2037-44.
163. Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-94.
164. CAPTURE I. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997; 349:1429-35.
165. PRISM. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998; 338: 1498-505.
166. PRISM-PLUS. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488-97.
167. PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436-43.
168. PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998; 97: 2386-95.
169. GUSTO-IV ACS Investigators. Effect of glycoprotein IIb/IIIA receptor blocker abciximab on outcome of patients with acute coronary syndromes without early revascularization: The GUSTO-IV ACS randomised trial. Lancet 2001; 357: 1915-24.
170. PARAGON-B investigators. Randomized, placebo-controlled trial of titrated IV Lamifiban for acute coronary syndrome. Circulation 2002; 105: 316-21.
171. Boersma E, Harrington R, Moliterno D et al. Platelet glycoproteinIIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98.
172. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non- ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767-71.
173. Steinhubl SR, Talley JD, Braden GA et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8.
174. Madan M, Tcheng JE. Update on abciximab readministration during percutaneous coronary interventions. Curr Interv Cardiol Rep 2000; 2: 244-9.
175. Madan M, Kereiakes DJ, Hermiller JB et al. Efficacy of abciximab readministration in coronary intervention. Am J Cardiol 2000; 85: 435-40.
176. Cohen M. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes. J Invas Cardiol 2000; 12 (Suppl E): E5-9; discussion E25-8.
177. James S, Armstrong P, Califf R et al. Safety and efficiency of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur Heart J 2002; 23: 1538-45.
178. TIMI IIIA investigators. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993; 87: 38-52.
179. Karlsson JE, Berglund U, Bjorkholm A, Ohlsson J, Swahn E, Wallentin L. Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: Effect on myocardial ischemia and need for coronary revascularization. TRIC Study Group. Am Heart J 1992; 124: 1419-26.
180. Schreiber TL, Macina G, McNulty A et al. Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction. Am J Cardiol 1989; 64: 840-4.
181. Schreiber TL, Macina G, Bunnell P et al. Unstable angina or non-Q wave infarction despite long-term aspirin: Response to thrombolytic therapy with implications on mechanisms. Am Heart J 1990; 120: 248-55.
182. Schreiber TL, Rizik D, White C et al. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation 1992; 86: 1407-14.
183. FTT Trialists. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343: 311-22.
184. FRISCII investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 708-15.
185. Van Belle E, Lablanche JM, Bauters C, Renaud N, McFadden EP, Bertrand ME. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: Natural history and the effect of thrombolysis. Circulation 1998; 97: 26-33.
186. Serruys PW, van Hout B, Bonnier H et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352: 673-81.
187. Lincoff AM, Califf RM, Anderson KM et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1997; 30: 149-56.
188. Lincoff AM. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization. Am J Cardiol 1998; 82: 36P-42P.
189. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
190. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-33.
191. Bjessmo S, Ivert T, Flink H, Hammar N. Early and late mortality after surgery for unstable angina in relation to Braunwald class. Am Heart J 2001; 141: 9-14.
192. Dyke CM, Bhatia D, Lorenz TJ et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT. Platelet Glycoprotein IIb/ IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg 2000; 70: 866-71; discussion 871-2.
193. Bizzarri F, Scolletta S, Tucci E et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122: 1181-5.
194. Clark SC, Vitale N, Zacharias J, Forty J. Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery. Ann Thorac Surg 2000; 69: 762-4; discussion 764-5.
195. Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: Tabular data compiled by the collaborative effort of the original trial investigators. Part 1 of 2. Online J Curr Clin Trials 1994; Doc No. 145.
196. Yusuf S, Zucker D, Chalmers TC. Ten-year results of the randomized control trials of coronary artery bypass graft surgery: Tabular data compiled by the collaborative effort of the original trial investigators. Part 2 of 2. Online J Curr Clin Trials 1994; Doc No. 144.
197. BARI investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. JAMA 1997; 277: 715-21.
198. CABRI Investigators. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularization Investigation. Circulation 1996; 93: 847.
199. RITA investigators. Coronary angioplasty versus coronary artery bypass surgery: The Randomized Intervention Treatment of Angina (RITA) trial. Lancet 1993; 341: 573-80.
200. King SB 3rd, Lembo NJ, Weintraub WS et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994; 331: 1044-50.
201. Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld W. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994; 331: 1037-43.
202. Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IF. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): In-hospital results and 1-year follow-up. ERACI Group. J Am Coll Cardiol 1993; 22: 1060-7.
203. Serruys PW, Unger F, Sousa JE et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344: 1117-24.
204. Lagerqvist B, Safstrom K, Stahle E, Wallentin L, Swahn E. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol 2001; 38: 41-8.
205. Exercise Physiology Working Group. Guidelines for cardiac exercise testing. Eur Heart J 1993; 14: 969-88.
206. Kontny F. Reactivation of the coagulation system: Rationale for long-term antithrombotic treatment. Am J Cardiol 1997; 80: 55E-60E.
207. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet 1990; 336: 827-30.
208. Antithrombotic Trialist Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
209. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-18.
210. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-6.
211. Stenestrand U, Wallentin L. Early revascularization and 1-year survival in 14-days survivors of acute myocardial infarction: A prospective cohort study. Lancet 2002; 359: 1805-11.
212. SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
213. SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [published erratum appears in N Engl J Med 1992 Dec 10; 327(24):1768]. N Engl J Med 1992; 327: 685-91.
214. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
215. Rabbani RTE. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999; 41: 402-17.
216. Yusuf S, Kostis JB, Pitt B. ACE inhibitors for myocardial infarction and unstable angina. Lancet 1993; 341: 829.
217. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
218. Dagenais GR, Yusuf S, Bourassa MG et al. Effects of ramipril on coronary events in high-risk persons: Results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001; 104: 522-6.